Company intelligence / Profile preview
DAAN Biotherapeutics
Seoul, Seoul, South Koreadaanbiotpx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DAAN Biotherapeutics is a Korean oncology biotech developing TCR- and T-cell–engager–based therapies, NK cell therapies, antibodies (including ADC-enabling antibodies), and small molecule inhibitors for solid tumors, particularly EGFR‑mutant lung cancer; its lead NK/TCR cell therapy and antibody programs are in preclinical development with plans for global clinical trials around 2026.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyTCR-T cell therapyNK cell therapyMonoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateSmall molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
LigaChem Biosciences – exclusive license for a novel tumor-targeting antibody for ADC development and commercialization in solid tumors.OmniAb – strategic partnership to build a proprietary pipeline of antibodies against overexpressed tumor targets in solid cancers.ACROBiosystems – strategic MOU to support antibody discovery/development; their materials used for DAAN’s lead antibody pipeline, which has completed preclinical development and is preparing for global trials.GenScript ProBio – CMO partnership for antibody development and manufacturing (ProBio provides CMO services for DAAN Bio Therapeutics’ antibodies).Korea Drug Development Fund (KDDF) – identified by KDDF/Nature feature as a Korean oncology innovator developing TCR and T-cell engager antibodies.
Beyond the preview
Go deeper on DAAN Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAAN Biotherapeutics.